Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across biomedical AI, cancer, cardiovascular diseases, immunity, age-related, rare and infectious diseases.

          Learn more

        • Biomedical AI
        • Cancer Innovations
        • Cardiovascular Research
        • Healthy Ageing
        • Infection & Immunity
        • Rare Diseases & Gene Therapy
        • Laboratories
        • Impact
        • Technologies
        • Commercialisation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research.

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your will
        • Donate in memory
        • Advise on our research
  • Careers & students
        • Careers & Students

          Postdoctoral and postgraduate students can work alongside world-leading medical researchers within state-of-the-art research facilities.

        • Careers
        • Study opportunities
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events.

        • News
        • Statements
        • Events
        • Real stories
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges.

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Animals in research
        • Contact
  • Donate
    Centenary Institute > News > Gene discovery linked to alcohol-induced liver disease

Gene discovery linked to alcohol-induced liver disease

Date time 27 August, 2020
News Type News type Media release
The findings of an international study led by the Centenary Institute suggests that the possibility of high-risk drinkers developing alcohol-induced cirrhosis is in part related to genetic factors.

“Only a small proportion of high-risk drinkers, about 15 percent, actually develop cirrhosis but those who do are at high risk of death and require substantial health-care support,” said senior author of the published study Clinical Associate Professor Devanshi Seth, Head of the Centenary Institute Alcoholic Liver Disease Research Program and also affiliated with Drug Health Services, Royal Prince Alfred Hospital, Sydney Local Health District.

“We wanted to see if certain high-risk drinkers had a genetic predisposition for alcohol-induced cirrhosis. High-risk drinking is chronic alcohol use above recommended guidelines,” said Clinical Associate Professor Seth.

Reported in the science journal ‘Hepatology’ the study was undertaken by a multi-national GenomALC Consortium involving the Southern California Institute for Research and Education (SCIRE) and other research collaborators.

Identified by the study researchers is a new gene associated with alcohol-induced cirrhosis. The novel FAF2 gene is associated with a reduced cirrhosis risk for heavy drinkers. Also confirmed by the study were four additional genes, three previously found to be associated with an increased risk and one with reduced risk of cirrhosis in heavy drinkers.

“Interestingly, a commonality of these genes, including the novel FAF2, is that they appear to affect the lipid (fat) metabolism pathway,” said Clinical Associate Professor Seth.

“The findings are important as due to heavy drinking, it is the build-up of lipid droplets in the liver, that can cause inflammation, and which may then lead to serious liver complications such as cirrhosis in some drinkers,” she said.

The researchers believe that the identified genes are influencing the body’s ability to regulate lipid droplets in the liver and are therefore influencing cirrhosis risk levels.

“This new understanding opens the door to the future development of exciting new drug treatments that can potentially target these specific genes and lipid processes, and reduce the chances of at-risk individuals contracting this devastating disease,” said Dr Timothy Morgan, co-senior author of the study and researcher at the SCIRE.

Clinical Associate Professor Seth says, “Abstaining or reducing alcohol use remains the most effective treatment, however fully understanding the genetic mechanics of alcohol-induced cirrhosis is also key to improving patient diagnosis and treatment decisions.”

“Identifying these genes at an individual level, in combination with assessing lifestyle options, means that we will now be able to predict an individual’s risk profile and then better personalise an appropriate treatment response,” she said.

The research was funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) a part of the National Institutes of Health (NIH), USA.

Read the full media release here.

Publication: Genome-wide association study and meta-analysis on alcohol-related liver cirrhosis identifies novel genetic risk factors.

Themes

  • Inflammation

    Inflammation

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw

Phone number Phone Number +61 402 770 403

Email Email t.crawshaw@centenary.org.au

Media Release

Download

Recent Stories

  • New grant targets longer-lasting islet cell treatments for type 1 diabetes

    Dr Lise Hunault, a researcher in the Centenary Institute’s Centre for Biomedical AI, has been awarded a major research grant from Breakthrough T1D, the leading global type 1 diabetes research and advocacy organisation, to advance islet-cell replacement therapies for type 1 diabetes.
    News Type: Research News
    Date 16 Mar 2026
  • Centenary marks International Women’s Day with inspiring speakers

    The Centenary Institute community came together to celebrate International Women’s Day 2026, with a special event highlighting this year’s Australian theme, ‘Balancing the Scales.’
    News Type: Community
    Date 11 Mar 2026
  • Vaxosome launched to develop next-generation mRNA vaccines

    A new biotechnology company, Vaxosome, has been launched to develop next-generation vaccines aimed at tackling some of the world’s most challenging infectious diseases.
    News Type: Research News
    Date 10 Mar 2026
  • Centenary partners in transformative national liver health program

    The Snow Medical Research Foundation has today announced major long-term funding of $15.5 million for a new national research program targeting fatty liver disease, a condition that affects up to one in three Australians. The Centenary Institute will play a key role in the collaborative effort.
    News Type: Research News
    Date 05 Mar 2026

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About us
  • Governance
  • Corporate information

Research

  • Our researchers
  • News

Careers & studies

  • Career opportunities
  • Student opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement
  • Staff Intranet

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Contact Privacy

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram